Healthcare / BiotechnologyWarsaw
$7.51
+0.05 (+0.67%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 34% · confianza 18%
FCF escenarios
weak_data · normalized FCF $-40.3M · quality 44.0/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
16/100
F
Piotroski
1/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$121M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-128.2%
↓Gross Margin
-110.5%
↓Debt/Equity
0.26
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-54.2%
FCF CAGR
—
FCF margin
-269.6%
FCF / Net income
0.68x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $15.8M · net income $-62.6M · FCF $-42.5M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $15.8M | $15.8M | $69.0M | $151.7M | $164.0M |
| Net Income | $-62.6M | $-62.6M | $-6.3M | $41.3M | $23.2M |
| EBITDA | $-52.8M | $-52.8M | $10.1M | $58.1M | $32.7M |
| EPS | — | — | -0.39 | 2.55 | 1.43 |
| Gross Margin | -110.5% | -110.5% | 59.6% | 75.5% | 40.2% |
| Operating Margin | -319.6% | -319.6% | -1.6% | 45.2% | 16.2% |
| Net Margin | -397.4% | -397.4% | -9.2% | 27.2% | 14.1% |
| Balance Sheet | |||||
| Debt/Equity | 0.26 | 0.26 | 0.03 | 0.30 | 0.10 |
| Current Ratio | 0.31 | 0.31 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-42.5M | $-42.5M | $27.5M | $-40.3M | $22.1M |
| Returns | |||||
| ROE | -128.2% | -128.2% | -5.7% | 35.0% | 30.3% |
| Valuation | |||||
| P/E | — | — | — | 7.92 | 15.86 |
| EV/EBITDA | — | — | 12.74 | 5.41 | 9.79 |
| P/B | 2.49 | 2.49 | 1.47 | 2.77 | 4.79 |
| Growth & Yield | |||||
| Revenue Growth | -77.2% | -77.2% | -54.5% | -7.5% | — |
| EPS Growth | — | — | -115.3% | 78.3% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-20.9%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.39 → n/d
Residual
-20.9%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.